Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
Fiche publication
Date publication
avril 2018
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Dr CLEMENT-DUCHENE Christelle, Pr FALCOZ Pierre-Emmanuel, Pr VIGNAUD Jean-Michel
Tous les auteurs :
Renaud S, Seitlinger J, Guerrera F, Reeb J, Beau-Faller M, Voegeli AC, Siat J, Clément-Duchêne C, Tiotiu A, Santelmo N, Costardi L, Ruffini E, Falcoz PE, Vignaud JM, Massard G
Lien Pubmed
Résumé
The prognostic value of exon 19 and 21 EGFR mutations in stage IV non-small cell lung cancer (NSCLC) is well established.
Mots clés
Adenocarcinoma, genetics, Aged, Biomarkers, Tumor, genetics, Carcinoma, Non-Small-Cell Lung, genetics, ErbB Receptors, genetics, Exons, Female, Follow-Up Studies, Humans, Lung Neoplasms, genetics, Male, Mutation, Neoplasm Staging, Retrospective Studies, Survival Rate
Référence
Ann. Surg. Oncol.. 2018 Apr;25(4):1069-1078